Abstract
Background Understanding the impact of non-pharmaceutical interventions remains a critical epidemiological problem in South Africa that reported the largest number of confirmed COVID-19 cases and deaths from the African continent.
Methods In this study, we applied two existing epidemiological models, an extension of the Susceptible-Infected-Removed model (eSIR) and SAPHIRE, to fit the daily ascertained infected (and removed) cases from March 15 to July 31 in South Africa. To combine the desirable features from the two models, we further extended the eSIR model to an eSEIRD model.
Results Using the eSEIRD model, the COVID-19 transmission dynamics in South Africa was characterized by the estimated basic reproduction number (R0) at 2.10 (95%CI: [2.09,2.10]). The decrease of effective reproduction number with time implied the effectiveness of interventions. The low estimated ascertained rate was found to be 2.17% (95%CI: [2.15%, 2.19%]) in the eSEIRD model. The overall infection fatality ratio (IFR) was estimated as 0.04% (95%CI: [0.02%, 0.06%]) while the reported case fatality ratio was 4.40% (95% CI: [<0.01%, 11.81%]). As of December 31, 2020, the cumulative number of ascertained cases and total infected would reach roughly 801 thousand and 36.9 million according to the long-term forecasting.
Conclusions The dynamics based on our models suggested a decline of COVID-19 infection and that the severeness of the epidemic might be largely mitigated through strict interventions. Besides providing insights on the COVID-19 dynamics in South Africa, we develop powerful forecasting tools that allow incorporating ascertained rate and IFR estimation and inquiring into the effect of intervention measures on COVID-19 spread.
Key Messages
This study delineated the COVID-19 dynamics in South Africa from March 15 to July 31 and confirmed the effectiveness of the main non-pharmaceutical intervention— lockdown, and mandatory wearing of face-mask in public places using epidemiological models;
COVID-19 spread in South Africa was found to be associated with both low ascertained rate and low infection fatality ratio;
According to the long-term forecast, by December 31, 2020, the cumulative number of ascertained cases and total infected would reach roughly 801 thousand and 36.9 million respectively.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the National Science Foundation [grant numbers DMS- 1712933 (to B.M.) and DMS-2015460 (to J.D.)] and from National Institute of Health [grant number 1 R01 HG008773-01 (to B.M.)]. The first and second author (X.G. and B.M.) would also like to thank the Center for Precision Health Data Sciences at the University of Michigan School of Public Health, The University of Michigan Rogel Cancer Center and the Michigan Institute of Data Science for internal funding that supported this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB was needed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.